Biotest AG — M&A Activity 2005

Jun 29, 2005

News Details

Corporate | 29 June 2005 13:13

Biotest AG: Biotest wins TANGO tender

Corporate-news transmitted by DGAP. The issuer is solely responsible for the content of this announcement. —————————————————————————— Biotest wins TANGO tender Dreieich, June 29, 2005. LBK Hamburg GmbH has awarded Biotest the tender for delivering, installing and servicing six fully automated TANGO blood grouping systems and the associated test reagents. This is the largest ever single order for this system, and will become binding after a 14-day objection period. The systems will be installed at all of the facilities operated by the Institut für Labormedizin, Mikrobiologie und Krankenhaushygiene (MEDILYS), which is part of the LBK Hamburg Group and which is one of Europe’s largest healthcare companies with a current total of seven hospitals and more than 20 service companies, subsidiaries and equity participations. The laboratory automation concept developed by Biotest gave a convincing performance in an European public tender thanks to its economic benefits. The TANGO analysis system automates all aspects of blood group and antibody diagnostics. Its standardized method guarantees a high degree of security when conducting blood-group serum tests. In a 24 h operation mode, the system replaces complex manual processing and hand-written documentation – thus resulting in faster, lower-cost laboratory processing – with constant high quality results. Information on Biotest AG Biotest AG, Dreieich, is a fully integrated pharmaceutical and diagnostics company with approximately 1,000 employees world-wide. Biotest is specialized in the development, production and marketing of therapeutic and diagnostic systems with a focus on clinical immunology, autoimmune diseases, haematology and intensive care medicine. The product portfolio includes human plasma derivatives such as immunoglobulin preparations and blood coagulation factors as well as test systems for cell diagnosis, transfusion diagnosis and tests for hygiene monitoring. In addition to further innovative plasma derivatives, Biotest’s therapeutic pipeline comprises several monoclonal antibody candidates. Biotest AG’s shares are admitted to Prime Standard trading. Investor Relations: Hubert Bötsch, Telephone: +49 (0) 6103 801-444, Telefax: +49 (0) 6103 801-880, E-mail: hubert_boetsch@biotest.de Biotest AG, Landsteinerstr. 5, D-63303 Dreieich, http://www.biotest.de WKN (German Securities Code), ISIN ordinary shares: 522720, DE0005227201 WKN (German Securities Code), ISIN preferred shares: 522723, DE0005227235 Listed: Prime Standard/Amtlicher Handel (Official Trading) Frankfurt, Berlin, Düsseldorf, Hamburg, Stuttgart End of announcement (c)DGAP 29.06.2005 —————————————————————————— WKN: 522720; ISIN: DE0005227201; Index: Listed: Amtlicher Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin- Bremen, Düsseldorf, Hamburg und Stuttgart 291313 Jun 05